Publications by authors named "Elena Revuelta-LoPEZ"

Soluble ST2 (sST2) is released in response to vascular congestion, inflammation, and pro-fibrotic stimuli. In heart failure (HF), elevated levels of sST2 are associated with a higher risk of adverse clinical outcomes. Emerging evidence suggests that carbohydrate antigen 125 (CA125) may act as a ligand that modulates the inflammatory response.

View Article and Find Full Text PDF
Article Synopsis
  • The PERISCOPE Phase I clinical trial assessed the safety of PeriCord, a tissue graft made from decellularised pericardial matrix and umbilical cord mesenchymal cells, in patients undergoing surgical revascularization after non-acute myocardial infarction.
  • In the trial, seven patients received PeriCord and demonstrated no adverse effects during the one-year follow-up, although there were no significant changes in overall quality of life or cardiac function compared to controls.
  • The study highlighted PeriCord's immunomodulatory effects, specifically in influencing the behavior of circulating monocytes towards a repair-promoting state, indicating potential for further exploration in treating inflammation-related conditions.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigated whether the PCSK9 inhibitor evolocumab could reduce troponin levels in patients with stable heart failure with reduced ejection fraction (HFrEF) of ischaemic origin, suggesting a potential to limit disease progression.* -
  • Conducted over one year, the trial compared the effects of evolocumab plus guideline-directed medical therapy (GDMT) against GDMT alone, finding no significant change in troponin levels but noted decreases in NT-proBNP and ST2 levels in the intervention group.* -
  • Results indicated a significant reduction in total and LDL cholesterol in the evolocumab group, while PCSK9 levels also increased, although the overall findings were limited and do not establish clear
View Article and Find Full Text PDF
Article Synopsis
  • Meteorin-like protein (Metrnl) is a cytokine that plays a role in reducing inflammation and its high levels are linked to poorer outcomes in heart failure patients.
  • This study focused on patients with ST-segment elevation myocardial infarction (STEMI) and measured Metrnl levels to evaluate its predictive power for health outcomes over three years.
  • Results showed that higher Metrnl levels correlated with greater risks of death or nonfatal heart attacks, indicating it could be a significant prognostic biomarker for complications in STEMI patients.
View Article and Find Full Text PDF
Article Synopsis
  • Myocardial fibrosis can worsen prognosis in heart failure patients, even if they show left ventricular reverse remodeling (LVRR) after treatment.
  • This study analyzed the levels of specific collagen-derived peptides in 1,034 heart failure patients to evaluate their association with heart function recovery and overall outcomes.
  • Results showed that patients with low levels of procollagen type I C-terminal propeptide (PICP) had better heart function improvements and lower risks of heart failure-related issues, especially in women and nonischemic cases.
  • The findings suggest that measuring PICP levels could help identify patients who are more likely to respond positively to treatment and enhance their clinical outcomes.
View Article and Find Full Text PDF

Objective: To assess the arrhythmic safety profile of the adipose graft transposition procedure (AGTP) and its electrophysiological effects on post-myocardial infarction (MI) scar.

Background: Myocardial repair is a promising treatment for patients with MI. The AGTP is a cardiac reparative therapy that reduces infarct size and improves cardiac function.

View Article and Find Full Text PDF

Primary ventricular fibrillation (PVF) is a life-threatening complication of ST-segment elevation myocardial infarction (STEMI). It is unclear what roles viral infection and/or systemic inflammation may play as underlying triggers of PVF, as a second hit in the context of acute ischaemia. Here we aimed to evaluate whether the circulating virome and inflammatory proteome were associated with PVF development in patients with STEMI.

View Article and Find Full Text PDF

Objectives: Heart failure (HF) management has significantly improved over the past two decades, leading to better survival. This study aimed to assess changes in predicted mortality risk after 12 months of management in a multidisciplinary HF clinic.

Materials And Methods: Out of 1,032 consecutive HF outpatients admitted from March-2012 to November-2018, 357 completed the 12-months follow-up and had N-terminal pro-B-type natriuretic peptide (NTproBNP), high sensitivity troponin T (hs-TnT), and interleukin-1 receptor-like-1 (known as ST2) measurements available both at baseline and follow-up.

View Article and Find Full Text PDF

Background: Lack of validation and standardization of research-use-only (RUO) immunoassays brings with it inherent threats to authenticity and functional quality. Poor correlation between different commercial neprilysin RUO immunoassays is concerning and discordant findings need to be resolved. We seek to identify and validate reliable neprilysin immunoassays to strengthen the scientific rigor and reproducibility of neprilysin-related investigation and of biomarker research in general.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers investigated the molecular changes following a heart attack (myocardial infarction) using microarray data from swine heart biopsies collected at various recovery stages.
  • Findings revealed that key processes like adipogenesis, fatty acid metabolism, and muscle contraction were significantly altered during the healing period, with angiogenesis emerging as a key early response.
  • The study identified critical genes involved in these processes, providing insights into potential biomarkers and therapeutic targets for better understanding heart post-infarction recovery.
View Article and Find Full Text PDF

To determine the effect of marathon running on serum levels of inflammatory, high energy, and cartilage matrix biomarkers and to ascertain whether these biomarkers levels correlate. Blood samples from 17 Caucasian male recreational athletes at the Barcelona Marathon 2017 were collected at the baseline, immediately and 48 h post-race. Serum C reactive protein (CRP), creatin kinase (CK), and lactate dehydrogenase (LDH) were determined using an AU-5800 chemistry analyser.

View Article and Find Full Text PDF

Clinical biomarker research is growing at a fast pace, particularly in the cardiovascular field, due to the demanding requirement to provide personalized precision medicine. The lack of a distinct molecular signature for each cardiovascular derangement results in a one-size-fits-all diagnostic and therapeutic approach, which may partially explain suboptimal outcomes in heterogeneous cardiovascular diseases (e.g.

View Article and Find Full Text PDF

The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear. Here we aimed to use artificial intelligence (AI) to characterize the mechanism of action of empagliflozin in HFpEF at the molecular level. We retrieved information regarding HFpEF pathophysiological motifs and differentially expressed genes/proteins, together with empagliflozin target information and bioflags, from specialized publicly available databases.

View Article and Find Full Text PDF

Introduction And Objectives: Microvascular obstruction (MVO) is negatively associated with cardiac structure and worse prognosis after ST-segment elevation myocardial infarction (STEMI). Epithelial cell adhesion molecule (EpCAM), involved in epithelium adhesion, is an understudied area in the MVO setting. We aimed to determine whether EpCAM is associated with the appearance of cardiac magnetic resonance (CMR)-derived MVO and long-term systolic function in reperfused STEMI.

View Article and Find Full Text PDF

Background: Circulating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value of sNEP in outpatients with HF and LVEF >57%, in comparison with patients with LVEF ≤57%.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to identify a specific CA125 level that can help determine which patients with acute heart failure (AHF) are at low risk for death or readmission within one month.
  • The research involved a large group of AHF patients and found that a CA125 level below 23 U/mL was associated with significantly lower risks for both death and readmission.
  • This cutoff value was validated with a separate patient group and demonstrated strong negative predictive values, suggesting that patients with CA125 levels under 23 U/mL could be safely monitored with less intensive follow-up.
View Article and Find Full Text PDF

A higher neprilysin activity has been suggested in women. In this retrospective analysis, we evaluated the association of sex and body mass index (BMI) with soluble neprilysin (sNEP) and recurrent admissions among 1021 consecutive HF outpatients. The primary and secondary endpoints were the number of HF hospitalizations and all-cause mortality, respectively.

View Article and Find Full Text PDF

Introduction: The association of pulmonary congestion assessed by lung ultrasound (LUS) and biomarkers-other than N-terminal pro-brain natriuretic peptide (NT-proBNP)-is uncertain.

Methods: We investigated the relationship between total B-line count by LUS and several biomarkers in outpatients with suspicion of heart failure (HF). Primary care patients with suspected new-onset nonacute HF were evaluated both with a 12-scan LUS protocol (8 anterolateral areas plus 4 lower posterior thoracic areas) and 11 inflammatory and cardiovascular biomarkers.

View Article and Find Full Text PDF

Objectives: This study investigated whether patients with chronic heart failure (HF) can be stratified according to the combination of soluble neprilysin and corin concentrations and whether this is related to clinical outcome.

Background: Natriuretic peptide processing by the enzymes corin and neprilysin plays a pivotal role in conversion of pro-natriuretic peptides to active natriuretic peptides, as well as their degradation, respectively.

Methods: A prospective cohort of patients with chronic HF (n = 1,009) was stratified into 4 equal groups based on high or low neprilysin/corin concentration relative to the median: 1) low neprilysin/low corin; 2) low neprilysin/high corin; 3) high neprilysin/low corin; and 4) high neprilysin/high corin.

View Article and Find Full Text PDF

Background: Identifying patients at risk of poor diuretic response in acute heart failure (AHF) is critical to make prompt adjustments in therapy. The objective of this study was to investigate whether the circulating levels of soluble ST2 predict the cumulative diuretic efficiency (DE) at 24 and 72 hours in patients with AHF and concomitant renal dysfunction.

Methods And Results: This is a post hoc analysis of the IMPROVE-HF trial, in which we enrolled 160 patients with AHF and renal dysfunction (estimated glomerular filtrate rate of <60 mL/min/1.

View Article and Find Full Text PDF

Objectives: The aim of this study was to evaluate the association between antigen carbohydrate 125 (CA125) and the risk of 1-year clinical outcomes in patients with worsening heart failure (HF).

Background: CA125 is a widely available biomarker that is up-regulated in patients with acute HF and has been postulated as a useful marker of congestion and risk stratification.

Methods: In a large multicenter cohort of patients with worsening HF, either in-hospital or in the outpatient setting, the independent associations between CA125 and 1-year death and the composite of death/HF readmission (adjusted for outcome-specific prognostic risk score [BIOSTAT risk score]) were determined by using the Royston-Parmar method (N = 2,356).

View Article and Find Full Text PDF
Article Synopsis
  • LRP1 is important for managing fat and glucose levels in the body, and its upregulation occurs in the heart during dyslipidemia.
  • Researchers created a mouse model with LRP1 deficiency specifically in heart cells to study how this impacts metabolism and heart function on a high-fat diet (HFD).
  • The study found that mice lacking LRP1 in cardiomyocytes maintained good heart function while resisting negative metabolic effects, linked to enhanced fat oxidation in the liver and increased signaling through ANP, highlighting the importance of LRP1 in regulating energy balance.
View Article and Find Full Text PDF